HR+/HER2- Metastatic Breast Cancer α-Specific PI3K inhibitors are emerging as potential treatment options for HR+/HER2- metastatic breast cancer.9 The PI3K pathway is the most frequently mutated signaling pathway across all breast cancer subtypes, and PIK3CA mutations are the most common alterations in the PI3K pathway10 Patients with HR+/HER2- metastatic breast cancer who have a PIK3CA […]

NSCLC Many patients diagnosed with early-stage NSCLC face a significant risk of recurrent disease and poor long-term outcome.11,12 For example, patients with ALK-positive NSCLC typically have a worse prognosis in the early stages than those with EGFR mutations13 Despite a similar prevalence of ALK mutations among Black and White populations, racial disparities exist in biomarker […]

CRC Certain mutations in tumor-suppressor genes are crucial biological triggers for CRC, with 80% of patients carrying common mutations in these genes.17   In metastatic CRC, patients who have mutations in the RAS family, mutations in BRAF, or MSI-H status have poor survival rates and shorter time to recurrence.18   Biomarkers targeting these mutations help with […]